Dupilumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adolescents 12 years and older who are candidates for systemic therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||17/12/2019|
|Rapid review completed||17/01/2020|
|Rapid Review outcome||A HTA is not recommended. The NCPE recommends that dupilumab not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013